Advertisement
Canada markets close in 2 hours 16 minutes
  • S&P/TSX

    21,941.99
    +148.09 (+0.68%)
     
  • S&P 500

    5,482.49
    +4.59 (+0.08%)
     
  • DOW

    39,218.96
    +91.16 (+0.23%)
     
  • CAD/USD

    0.7308
    +0.0009 (+0.13%)
     
  • CRUDE OIL

    81.47
    +0.57 (+0.70%)
     
  • Bitcoin CAD

    84,517.34
    +1,089.78 (+1.31%)
     
  • CMC Crypto 200

    1,289.77
    +23.62 (+1.87%)
     
  • GOLD FUTURES

    2,337.50
    +24.30 (+1.05%)
     
  • RUSSELL 2000

    2,029.36
    +11.24 (+0.56%)
     
  • 10-Yr Bond

    4.2830
    -0.0330 (-0.76%)
     
  • NASDAQ

    17,863.25
    +58.09 (+0.33%)
     
  • VOLATILITY

    12.41
    -0.14 (-1.11%)
     
  • FTSE

    8,179.68
    -45.65 (-0.55%)
     
  • NIKKEI 225

    39,341.54
    -325.53 (-0.82%)
     
  • CAD/EUR

    0.6824
    -0.0007 (-0.10%)
     

Sarepta Stock Surges on Expanded Elevidys Approval. It’s a ‘Best-Case’ Scenario for Shares.

Sarepta Stock Surges on Expanded Elevidys Approval. It’s a ‘Best-Case’ Scenario for Shares.

The biopharmaceutical company says the drug was approved for ambulatory and non-ambulatory people, who are at least 4 years old, and with a confirmed mutation in the DMD gene.